These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 16336326

  • 1. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M.
    BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M, AUO-AB 05/95.
    J Clin Oncol; 2005 Aug 01; 23(22):4963-74. PubMed ID: 15939920
    [Abstract] [Full Text] [Related]

  • 4. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Birtle AJ, Huddart RA.
    BJU Int; 2006 Jun 01; 97(6):1348; author reply 1348-50. PubMed ID: 16686740
    [No Abstract] [Full Text] [Related]

  • 5. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct 01; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Int J Urol; 2008 Apr 01; 15(4):314-8. PubMed ID: 18380818
    [Abstract] [Full Text] [Related]

  • 8. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
    Sahwi A, Robert M, Delbos O, Legouffe E, Guiter J, Navratil H.
    Prog Urol; 1998 Dec 01; 8(6):1007-11. PubMed ID: 9894259
    [Abstract] [Full Text] [Related]

  • 9. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD, Petrylak DP, Singh P, Bagiella E, O'Toole KM, Benson MC, Olsson CA.
    J Urol; 2000 May 01; 163(5):1413-8. PubMed ID: 10751847
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
    Freiha F, Reese J, Torti FM.
    J Urol; 1996 Feb 01; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
    Lehmann J, Retz M, Stöckle M.
    World J Urol; 2002 Aug 01; 20(3):144-50. PubMed ID: 12196897
    [Abstract] [Full Text] [Related]

  • 12. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O.
    Int J Clin Oncol; 2005 Apr 01; 10(2):133-8. PubMed ID: 15864700
    [Abstract] [Full Text] [Related]

  • 13. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN, Pansadoro V, Calabrò F, Schnetzer S, Giannarelli D, Emiliozzi P, De Paula F, Scarpone P, De Carli P, Pizzo M, Platania A, Amini M.
    Cancer; 2003 Apr 01; 97(7):1644-52. PubMed ID: 12655521
    [Abstract] [Full Text] [Related]

  • 14. Surgical factors influence bladder cancer outcomes: a cooperative group report.
    Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED.
    J Clin Oncol; 2004 Jul 15; 22(14):2781-9. PubMed ID: 15199091
    [Abstract] [Full Text] [Related]

  • 15. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F.
    Cancer; 2004 Dec 01; 101(11):2540-8. PubMed ID: 15481058
    [Abstract] [Full Text] [Related]

  • 16. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N.
    J Urol; 1996 Jun 01; 155(6):1897-902. PubMed ID: 8618282
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
    Walz J, Shariat SF, Suardi N, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI.
    BJU Int; 2008 Jun 01; 101(11):1356-61. PubMed ID: 18454792
    [Abstract] [Full Text] [Related]

  • 18. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct 01; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA, Bex A, Meinhardt W, Kerst JM, Schornagel JH, VAN Tinteren H, Horenblas S.
    J Urol; 2005 Jul 01; 174(1):80-5. PubMed ID: 15947583
    [Abstract] [Full Text] [Related]

  • 20. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.
    Solsona E, Climent MA, Iborra I, Collado A, Rubio J, Ricós JV, Casanova J, Calatrava A, Monrós JL.
    Eur Urol; 2009 Apr 01; 55(4):911-9. PubMed ID: 18722046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.